CD8A and neoplasm: First, we administered a monoclonal antibody that depletes CD8+ cells (Supplementary Fig. 10) into tumor-bearing mice, 2 days before starting the treatment with anti-GARP:TGF-β1 WT and anti-PD-1 WT mAbs.